Model Neurodegenerative Disease Traits More Closely
Whitepaper
Last Updated: December 5, 2023
(+ more)
Published: November 29, 2023
credit: iStock
Existing neurodegenerative disease models rely on the use of transgenic mouse models that often do not completely reproduce the natural disease progression in humans.
Pre-formed fibrils (PFFs) are a novel tool generated in vitro that can imitate endogenous protein aggregation in both animal and cellular models. As such, PFFs enable the creation of a model that more closely aligns with the traits found in neurodegenerative diseases.
This whitepaper highlights how PFFs could become the breakthrough modeling platform for scientists to discover and develop the next therapeutic for neurodegenerative diseases.
Download this whitepaper to learn more about:
- Current neurodegenerative disease models
- The applications of pre-formed fibrils
- Cost-effective insights into your neurodegenerative disease research
w w w . a c r o b i o s y s t e m s . c o m
Pre-formed Fibrils:
Another perspective in modelling
of neurodegenerative diseases
Neurodegenerative diseases inflict a substantial burden on both personal, societal, and public health across the
globe. These progressive neurological disorders feature a set of debilitating, incurable diseases that are increasing
in prevalence, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). Together, both AD and PD afflicts
over 130 million people worldwide, with its prevalence rising dramatically with age. This number is only expected
to increase in the foreseeable future as life spans continue to increase. Unfortunately, neurodegenerative disease
research has been limited by an inadequate understanding or incomplete perspective into disease pathology. This, in
turn, has translated into a poor track record in developing neurodegenerative treatments and discovering new
therapeutic avenues.
Elucidating disease pathology has been heavily driven through the use of in vitro and in vivo models; both essential tools
in providing new insights into disease progression, cellular mechanisms, and much more. In the case of
neurodegenerative diseases, our limited comprehension is in part due to the use of premature experimental models.1
Existing neurodegenerative disease models relies on the use of transgenic mouse models with knock-out or
over-expressed pathogenic genes and proteins. However, these models often do not completely reproduce the natural
disease progression and are an incomplete imitation of neurodegeneration. Pre-formed fibrils (PFFs) are a novel tool
for modeling AD and PD which are being increasingly used in related studies. These fibrils are generated in vitro and can
imitate endogenous protein aggregation in both animal and cellular models. As such, PFFs enable the creation of a
model that more closely aligns with the traits found in neurodegenerative diseases including ‘seeding’ and ‘transmission’ of the
related pathogenic proteins. In this article, we first discuss the limitations of current disease models before discussing
in-depth about PFFs and its current applications in neurodegenerative research.
A hallmark of neurodegenerative diseases is protein misfolding and aggregation of proteins that results in cellular
dysfunction, loss of synaptic connections, and brain damage. Although the protein that aggregates may differ
between neurodegenerative diseases, the disease progression and clinical indications are similar. To study these
diseases, most of these experimental models are animal models involving the use of transgenic rodent animals
expressing human genes to induce pathogenic protein aggregation, especially AD. Similarly, chemically or physically
induced animal models are also employed as these models are able to capture certain symptoms of diseases that
may not be modelled in transgenic mice, such as PD.
Introduction
Current Neurodegenerative Disease Models
Figure 1. Amyloid aggregation associated with neurodegenerative diseases. Reproduced from Stroo et al. 2
01
AD disease models use transgenic mice: these models generally only exhibit amyloid accumulation, a defining
characteristic of AD, but lack neurofibrillary tangle (NFT) development. NFTs are a secondary characteristic of AD
that are insoluble twisted fibers inside of brain cells. These tangles are formed through a misfolded tau protein
that are the constituents of microtubules. These microtubules transport nutrients and other molecules between
nerve cells; the formation of NFTs causes the collapse of these microtubule structures. Within the transgenic
mouse models, endogenous mouse tau inhibits the aggregation of human tau and only express 4R tau isoforms, unlike
the mixture of 3R and 4R isoforms in AD. To overcome the non-formation of NFTs, transgenic mice were modified
to express 4R human tau with a P301L or P301S mutation. However, this reduces the accuracy of the mouse
model, as these mutations are not associated with AD and may potentially influence toxicity or interaction with the
amyloid plaques through pathways not reflective of AD. Furthermore, the overexpression of these mutated tau
proteins results in motor deficits not associated with AD and interferes with cognitive testing.3
To model PD, toxin-induced mouse models such as 6-OHDA and MPTP, are the classical model choice and are widely
in-use. By introducing neurotoxins into the animal models, rapid degeneration of dopaminergic neurons in PD-related
regions lead to a robust and well-characterized motor deficit. However, this model only simulates the clinical
symptoms and lacks the molecular pathology of PD, such as alpha-synuclein (α-syn) accumulation and Lewy
bodies. On the other hand, transgenic mice with mutations in SNCA, LRRK2, Parkin, PINK1 and DJ-1 are also used to
study PD. These genetic mutations are linked to inherited forms of PD and express the implicated proteins. However, these
transgenic mouse models often lack the same robust nigrostriatal degeneration (loss of dopamine neurons) and do not
have the same consistent, reproducible motor deficits as with the toxin-induced models.
Unlike transgenic and toxin-induced mouse models, PFFs provide a different and more cost-effective perspective
into neurodegenerative disease research. Whereas transgenic mouse models focus on selecting certain genetic
mutations to express pathogenic proteins endogenously, the genetic differences between host and target could
cause some complications. This is most notable with the lack of NFT formation due to the inhibition of expressed
human tau by endogenous mouse tau. On the other hand, toxin-induced models simulate the clinical symptoms in
a reproducible format but lack the molecular pathology needed to understand disease progression. PFFs are a
more direct methodology, injecting pre-formed pathogenic fibrils to form protein aggregates and induce
neurodegeneration. This method not only induces the molecular pathology faster than transgenic mice, but also
reduces the scientific burden and length of time for mouse maturation. Similarly, PFFs are useable at the in vitro
level, enabling a direct, more reproducible method to identify and measure disease pathology while providing
scientists a model to test new drug candidates.
Pre-formed Fibrils and Formation
Figure 2. Immunohistochemical GFAP staining of the substantia nigra pars compacta region in a mouse brain.
Optical density analysis of GFAP-positive cells reveals an increased amount of astrogliosis in PFF α-syn treated
mice in comparison to monomer α-syn, revealing neuroinflammation associated with α-syn accumulation. Reproduced
from Earls 2019.4
02
PFFs are easily formed from protein monomers by incubating at 37°C and shaking with or without heparin. Each
protocol depending on the protein monomer of choice depends on the monomers’ ability and tendency to
aggregate. For example, tau-441 PFFs require a concentration of 2 mg·mL-1 with heparin, while shaking and incubating for
7 days. In contrast, alpha-synuclein PFFs are incubated without heparin at an initial monomer concentration of 5
mg·mL-1. For other mutated monomers or pathogenic fragments such as alpha-synuclein A53T or tau K18
P301L, incubation time can be much shorter (4-5 days) due to its increased tendency to aggregate.
Verification of PFFs is also critical before implementation as disease models. The presence of fibrillary structures
should be visually verified through microscopy and chemically through ThT assays. ThT assays help analyze the
structure of high molecular weight species and determine whether the typical cross-beta structure has been
formed. Similarly, size and morphology of aggregates should be confirmed through transmission electron
microscopy (TEM) or atomic force microscopy. In addition, the length of the formed fibrils is important in
pathogenicity. Thus, before use, PFFs should be sonicated into 50 nm or smaller seeds before experiments; both
of which can be visualized through TEM or dynamic light scattering.
Figure 3. Transmission Electron Microscopy of Human Tau-441/2N4R pre-formed fibrils. Protein aggregates with
distinct fibrous structures are visible with accurate morphology.
03
Tau PFF models for AD study and drug development are well established in cellular systems including
neurons, microglia, and astrocytes. Studies evaluating PFF addition to cultured cells have indicated that the tau
PFFs are internalized by cells through endocytosis and serve as a seed to recruit endogenous tau to adopt misfolded
conformations.5,6 After internalization of tau PFFs, intracellular fibrilization of endogenous tau was induced. After
recruitment, tau aggregates are externalized through degenerating axons or somatodendritic compartments via
secretion or other undiscovered mechanisms. The externalized tau aggregates are then adopted by surrounding or
interconnected neurons, sustaining the theorized template for the propagation of tau pathology. In contrast to
cell-based models, animal-based tau PFF models have proven to be more of a challenge to establish. Injection of
heparin-induced wild-type tau-441 PFFs were found to have a limited seeding capacity and instead, require the
combination of transgenic mice and truncated tau-PFFs to achieve AD-like protein aggregations. In one study, in
vivo studies were established through the hippocampal or frontal cortex injection of truncated tau PFFs into tau Tg
mice expressing human mutant P301L tau. 7 Through the combination of both transgenic mouse and PFF
models, both induction of tau fibrillization and spreading of tau pathology to interconnected brain regions was
observed. Neuronal loss in hippocampus was observed, leading to the discovery of a new in vivo model for tau
pathological spread with neurodegeneration.
Current Applications of Pre-formed Fibrils
Figure 4. Nissl staining of the hippocampus of P301L mice injected with buffer or truncated tau PFFs. AT8 (green,
identifier of tau-presence) was apparent in mice treated with PFFs and shown to preceed neuronal loss found in
the 3 month post-injection mice. Reproduced from Peeraer 2015.7
Figure 5. α-Syn immunostaining of substantia nigra pars compacta of mice following intrastriatal PFF injection.
Lewy-body like inclusions (black arrows) were observed in ipsilateral sections but were not observed in contralateral
sections; this supports the theory of a cell-to-cell transmission method for Lewy-bodies comprised of misfolded
α-syn. Reproduced from Luk 2012.11
04
In PD, α-syn PFF models are commonly used to model the two major disease processes: accumulation of intraneuronal
Lewy-bodies/neurites and selective degeneration of midbrain dopamine neurons. Whereas tau PFFs struggle to induce
protein aggregations in vivo, α-syn PFF models have been well-established in both in vitro and in vivo. In vitro models have been
well established targeting primary neurons8, human iPSC-derived dopaminergic neurons9, and organ-on-a-chip10, all of
which serve as efficient tools for high-throughput drug screening and testing. Similarly, α-syn PFFs efficiently seed
aggregation and fibrillization of endogenous α-syn in wild-type mice. In one study, α-syn PFFs were injected, targeting the
dorsal striatum, which resulted in the identification of hyperphosphorylated deposits of α-syn. 11 After 30 days
post-injection, the Lewy-body like accumulations travelled along the inter-neural connectivity, suggesting a cell-to-cell
transmission method. Clinical symptoms related to PD were also observed, including impaired balance and motor
coordination. Overall, a single intra-striatal injection of misfolded α-syn PFFs was sufficient to initiate the neurodegenerative
cascade associated with PD, including Lewy-body pathology, dopaminergic neuron loss, and impaired motor function.
05
Overall, pre-formed fibrils are novel tools that model a more ‘natural’ pathophysiology of neurodegenerative
diseases, including AD and PD. PFFs mimic the seeding and transmission activity of pathogenic proteins and can be used for
both in vivo and in vitro models. As such, compared to transgenic mouse and toxin-induced models, PFFs have been shown to
better replicate major neurodegenerative disease hallmarks with less scientific burdens.
Despite PFFs models finding success in academic research, the application of these models is limited in clinical, industry-driven
research. Without stable, quantifiable phenotypes as well as reproducible protocols, PFF-based modelling will continue to
find a limited application in large-scale drug screening and testing. However, many scientists and industries have dedicated
efforts into dissecting the structural features and activity mechanisms of PFFs in disease models. With a deeper understanding of
these characteristics, higher quality PFFs can be produced which helps provide more in-depth examinations into
neurodegenerative diseases. In turn, PFFs could become the breakthrough modeling platform for scientists to discover and
develop the next therapeutic for neurodegenerative diseases.
Discussion
1.Gitler AD, Dhillon P, Shorter J. Neurodegenerative disease: models, mechanisms, and a new hope. Dis Model Mech. 2017; 10
(5):499-502
2.Stroo E, Koopman M, Nollen EA, Mata-Cabana A. Cellular Regulation of Amyloid Formation in Aging and Disease. Front Neurosci.
2017; 14;11:64.
3.Drummond E, Wisniewski T. Alzheimer's disease: experimental models and reality. Acta Neuropathol. 2017; 133(2):155-175.
4.Earls, R.H., Menees, K.B., Chung, J. et al. Intrastriatal injection of preformed alpha-synuclein fibrils alters central and peripheral
immune cell profiles in non-transgenic mice. J Neuroinflammation. 2019; 16, 250.
5.Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 2009;
284:12845‒12852.
6.Guo JL, Lee VM. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J. Biol. Chem.
2011; 286:15317‒15331.
7.Peeraer E, Bottelbergs A, Van Kolen K, et al. Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy
and neuronal loss in the brains of tau transgenic mice. Neuroboi l Dis. 2015; 73:83-95.
8.Volpicelli-Daley LA, Luk KC, et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and
neuron death. Neuron. 2011; 72(1):57-71.
9.Tanudjojo, B., Shaikh, S.S., Fenyi, A. et al. Phenotypic manifestation of α-synuclein strains derived from Parkinson’s disease and
multiple system atrophy in human dopaminergic neurons. Nat Commun. 2021; 12, 3817.
10.Pediaditakis I, Kodella KR, Manatakis DV, et al. Modeling alpha-synuclein pathology in a human brain-chip to assess blood-brain
barrier disruption. Nat Commun. 2021;12(1):5907.
11.Luk KC, Kehm V, Carroll J, et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic
mice. Science. 2012; 338(6109):949-53.
References
Additional Resource
Aneuro | Pre-formed Fibrils (PFFs)
Copyright
Statement
This material is copyrighted by the Company.
All rights in this material are reserved by the
Company. Unless otherwise indicated in writing, all
material in this material is copyrighted by
the Company. No part of this material may
be copied, photocopied or reproduced in any
form or redistributed to any other person or
used in any other manner which infringes the
Company's copyright without the prior written
authorisation of the Company.
www.acrobiosystems.com
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Email: order@acrobiosystems.com
Address: 1 Innovation Way, Newark, DE 19711, USA
Brought to you by
Download the Whitepaper for FREE Now!
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.